Research Article

Anti-IL-17 Antibody Improves Hepatic Steatosis by Suppressing Interleukin-17-Related Fatty Acid Synthesis and Metabolism

Figure 2

Serum IL-17 levels as determined by ELISA in the different stages of ALD. (a) Control group, (b) ALD (4W) group, (c) ALD (8W) group, (d) ALD (12W) group, and (e) Anti-IL-17 antibody treated ALD group. The data indicate Mean ± SEM of three separate experiments. ; .
253046.fig.002